Vincent Milano Biography and Net Worth

Vincent J. Milano CPA serves as President, Chief Executive Officer, Director of the Company. Prior to joining us, Mr. Milano served as Chairman, President and Chief Executive Officer of ViroPharma Inc., which was acquired by Shire Plc in January 2014, from March 2008 to January 2014, as its Vice President, Chief Financial Officer and Chief Operating Officer from January 2006 to March 2008 and as its Vice President, Chief Financial Officer and Treasurer from April 1996 to December 2005. Mr. Milano also served on the board of directors of ViroPharma from March 2008 to January 2014. Prior to joining ViroPharma, Mr. Milano served in increasingly senior roles, most recently senior manager, at KPMG LLP, an independent registered public accounting firm, from July 1985 to March 1996. Mr. Milano currently serves on the board of directors of Spark Therapeutics, Inc. and Vanda Pharmaceuticals Inc., each a publicly traded company, and VenatoRx Pharmaceuticals, Inc. Mr. Milano holds a Bachelor of Science degree in Accounting from Rider College. He also has corporate governance experience through service on other public company boards.

What is Vincent Milano's net worth?

The estimated net worth of Vincent Milano is at least $317,593.04 as of December 24th, 2018. Mr. Milano owns 55,816 shares of BioCryst Pharmaceuticals stock worth more than $317,593 as of December 10th. This net worth evaluation does not reflect any other assets that Mr. Milano may own. Learn More about Vincent Milano's net worth.

How do I contact Vincent Milano?

The corporate mailing address for Mr. Milano and other BioCryst Pharmaceuticals executives is 4505 EMPEROR BOULEVARD SUITE 200, DURHAM NC, 27703. BioCryst Pharmaceuticals can also be reached via phone at (919) 859-1302 and via email at [email protected]. Learn More on Vincent Milano's contact information.

Has Vincent Milano been buying or selling shares of BioCryst Pharmaceuticals?

Vincent Milano has not been actively trading shares of BioCryst Pharmaceuticals within the last three months. Most recently, on Wednesday, November 24th, Vincent Milano bought 7,500 shares of BioCryst Pharmaceuticals stock. The stock was acquired at an average cost of $12.19 per share, with a total value of $91,425.00. Learn More on Vincent Milano's trading history.

Who are BioCryst Pharmaceuticals' active insiders?

BioCryst Pharmaceuticals' insider roster includes George Abercrombie (Director), Yarlagadda Babu (Insider), Alane Barnes (Insider), Anthony Doyle (CFO), Nancy Hutson (Director), Vincent Milano (Director), William Sheridan (Insider), and Jon Stonehouse (CEO). Learn More on BioCryst Pharmaceuticals' active insiders.

Are insiders buying or selling shares of BioCryst Pharmaceuticals?

During the last twelve months, insiders at the biotechnology company sold shares 6 times. They sold a total of 127,370 shares worth more than $1,324,621.75. The most recent insider tranaction occured on June, 15th when Director Machelle Sanders sold 4,000 shares worth more than $31,920.00. Insiders at BioCryst Pharmaceuticals own 4.4% of the company. Learn More about insider trades at BioCryst Pharmaceuticals.

Information on this page was last updated on 6/15/2023.

Vincent Milano Insider Trading History at BioCryst Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/24/2021Buy7,500$12.19$91,425.00View SEC Filing Icon  
See Full Table

Vincent Milano Buying and Selling Activity at BioCryst Pharmaceuticals

This chart shows Vincent Milano's buying and selling at BioCryst Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

BioCryst Pharmaceuticals Company Overview

BioCryst Pharmaceuticals logo
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor for complement-mediated diseases; and Galidesivir, to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Read More

Today's Range

Now: $5.69
Low: $5.59
High: $5.82

50 Day Range

MA: $5.73
Low: $4.98
High: $6.77

2 Week Range

Now: $5.69
Low: $4.82
High: $12.07


5,120,367 shs

Average Volume

3,669,082 shs

Market Capitalization

$1.17 billion

P/E Ratio


Dividend Yield